Clinical trial · Observational
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
Pharmacodynamic Study of Fibroblast Activity Protein in Patients With Localized Pancreas Cancer Undergoing Surgical Resection
NCT00900016CI-TRIAL-00029478completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is assessing fibroblast activity in patients with localized pancreatic cancer undergoing surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immunohistochemistry staining method | Other | — | UNRESOLVED |
| immunologic technique | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| protein expression analysis | Genetic | — | UNRESOLVED |
| western blotting | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Independence of tumor fibroblast activation protein (FAP) activity and Met-α2-antiplasmin expression
- timeFrame
- Within 28 days for prior to surgery and at 3 month intervals for up to 2 years or recurrence
Secondary outcomes (2)
- measure
- Feasibility of exploiting the circulatory compartment to identify surrogates of tumor FAP
- timeFrame
- Within 28 days for prior to surgery and at 3 month intervals for up to 2 years or recurrence
- measure
- Potential plasma surrogates of plasma dipeptidyl peptidase activity and plasma antiplasmin converting enzyme
- timeFrame
- Within 28 days for prior to surgery and at 3 month intervals for up to 2 years or recurrence
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Biopsy-proven adenocarcinoma of the pancreas or pancreatic mass suspicious for pancreatic cancer * Localized disease * Scheduled to undergo a resection or exploration of their pancreatic tumor PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available
No reference posted for this study.